Impact of spectral OCT on clinical retinology

Article

Spectral (fourier domain) optical coherence tomography (SOCT) represents a significant development in the field of retinal imaging.

A great deal of information about the physical background of SOCT and the improved quality of images produced by the technology has been presented in recent literature. However, there is very little information regarding the clinical advantages of using this technique; in peer review literature we found only 13 papers presenting both clinical data and demonstration of imaging possibilities. This is probably because of the limited availability of SOCT instruments. The majority of papers describe experimental devices, the use of which is very expensive and not common in daily clinical practice.

New spectral domain OCT devices, manufactured by a number of firms, have however, been making their way to the market recently and, as such, the number of scientific papers reporting on these technologies is expected to grow rapidly. These new devices include Topcon's SOCT (3DOCT-1000), the Spectralis family (Heidelberg Engineering), RTVue-100 (Optovue), Copernicus (Optopol), Spectral OCT/SLO (OTI) and Cirrus HD-OCT (Zeiss). We have been using the commercially available Copernicus OCT in our retina outpatient clinic since February 2006.

Is SOCT better than standard OCT?

Earlier this year, McDonald and co-workers1 confirmed the ability of standard OCT to measure retinal thickness with a high degree of accuracy and reproducibility. However, a team led by Wojtkowski delved deeper and was able to show that measuring retinal thickness with high resolution spectral OCT was more accurate when compared with its standard counterpart.2

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Related Content
© 2025 MJH Life Sciences

All rights reserved.